. 2021 Nov 18;74:101679. doi: 10.1016/j.tice.2021.101679

Table 1.

Clinicopathological characteristics moderate COVID-19 patients and controls.

Group	Variable
Group	Control (n = 50) (Mean ± SD)	Moderate COVID-19 without GIT (n = 98) (Mean ± SD)	Moderate COVID-19 with GIT (n = 63) (Mean ± SD)
Age (yrs)	45.80 ± 8.82	48.36 ± 9.14	51.54 ± 9.15^*, ^a
Gender (n (%))
Male	32(64 %)	56(57.2 %)	42(66.7 %)
Female	18(36 %)	42(42.8 %)	21(33.3 %)
AST (U/L)	22.05 ± 9.37^*, ^b,^c	33.15 ± 21.97^*, ^a	36.60 ± 20.07^*, ^a
ALT (U/L)	19.35 ± 7.71^*, ^b,^c	34.44 ± 23.56^*, ^a	34.45 ± 19.26^*, ^a
Urea (mg/dl)	32.05 ± 6.57^*, ^b,^c	40.71 ± 14.48^*, ^a	42.88 ± 5.02^*, ^a
Creatinine (mg/dl)	0.93 ± 0.22^*, ^b	1.22 ± 0.35^*, ^a	1.0 ± 0.16
CRP (mg/dl)	4.99 ± 1.57^**, ^b,^c	75.04 ± 39.50^**, ^a	76.35 ± 12.9^**, ^a
WBCs (10^3/μl)	7.47 ± 2.05^*, ^b,^c	10.03 ± 4.17^*, ^a	10.13 ± 4.62^*, ^a
Neutrophils (%)	65.00 ± 5.06^*, ^b,^, ^c	73.76 ± 7.19^**, ^a	76.95 ± 5.57^**, ^a
Lymphocytes (%)	29.60 ± 5.30^**, ^b,^c	19.89 ± 6.94^**, ^a	20.41 ± 6.13^**, ^a
Ferritin (ng/mL)	104.35 ± 50.85^*, ^b,^c	213.86 ± 135.24^*, ^a	221.85 ± 186.49^*, ^a
Serum electrolytes
• K (mmol/L)	8.06 ± 0.68^**, ^b,^c	3.81 ± 0.38^**, ^a,^c	2.68 ± 0.89^**, ^a,^b
• Na (mmol/L)	143.7 ± 7.50^, ^b,^*, ^c	138.76 ± 4.73^, ^a, ^*, ^c	127.95 ± 11.27^**, ^a,^b
• Ca (mg/dl)	9.06 ± 0.69^*, ^b,^c	8.039 ± 0.80^*, ^a	8.095 ± 1.029^*, ^a
• Mg (mmol/L)	0.86 ± 0.08	0.86 ± 0.12	0.87 ± 0.11
• Cl (mmol/L)	99.42 ± 3.45	98.82 ± 3.35	99.23 ± 4.48
GIT manifestations
• Anorexia	-----------	-----------	38.1 % (24/63)
• Diarrhea			31.7 % (20/63)
• Vomiting & nausea			20.6 % (13/63)
• Abdominal pain			9.5 % (6/63)

Significant at p-value < 0.05.

^**

Highly significant at p-value < 0.001.

Significant difference versus Control group.

Significant difference versus Without GIT group.

Significant difference versus With GIT group.